Jesus Almendral, MD, and Kanika Mody, MD, join the HCPLive team to discuss increases in hypertensive heart disease, heart failure, and other conditions.
News|Articles|July 3, 2026
9 Cardiology Headlines You Missed in Q2 2026
Author(s)Ryan Livingston
Fact checked by: Abigail Brooks, MA
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Advertisement
Advertisement
The second quarter of 2026 saw an influx of major cardiology news, with the US Food and Drug Administration (FDA) approving some significantly beneficial drugs and a slew of conferences providing key clinician insights into ongoing and completed trials. Everything from heart failure to cardiomyopathy was highlighted over the last 3 months – in fact, an entirely new form of the former was established formally by the Heart Failure Society of America (HFSA) in May.
Related to this article
Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.
Get a head start on one of the biggest heart failure conferences of the year with our HFSA 2026 preview.
Higher levels of Lp(a) are also associated with deep vein thrombosis and pulmonary embolism according to this retrospective cohort study.
FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.
FDA approved mavacamten for oHCM in children weighing 30 kg or more after SCOUT-HCM showed a 48.0-mm Hg Valsalva LVOT gradient reduction vs placebo.
Preview the biggest anticipated FDA decisions of Q4 2026, including bepirovirsen for CHB, obinutuzumab for pMN, bezuclastinib for systemic mastocytosis, and more.
Real-world COMPETE SWITCH CV data at EASD 2026 linked semaglutide 2 mg escalation to 6% lower MACE risk vs switching to tirzepatide in T2D.
Advertisement
Advertisement